Also, the MS (minimum of 20 months follow-up) for cohort 1 was 23.5 months, cohort two was 15.5, and cohort 3 was 13.2 months. Thus, the trial showcased responses with good tolerability for Atezolizumab monotherapy in advanced-stage NSCLC patients with PD-L1 selected tumors. Here, CD274 is linked to non-small cell lung carcinoma.